. 2016 Feb;23(6):520–577. doi: 10.2174/0929867323666151223095839

Table 17. Banyu eukaryotic and prokaryotic biochemical and cellular data for enantiomers 116 and 125 and in vivo antitumor activities in 3 murine models. Etoposide and ciprofloxacin were used as controls.

In vitro or in vivo assay			14 etopo-side	15 cipro-floxacin
E. coli gyrase DNA supercoiling IC₅₀ (μg/ml)^a	0.2	1.0	*	1.0
L1210 topo II DNA relaxation IC₅₀ (μg/ml)^a	1.5	24	4.4	> 50
L1210 topo II induction of DNA cleavage IC₅₀ (μg/ml)^a	1.2	> 12	½ as active vs of (-)-BO	*
L1210 topo II induction of DNA cleavable complex formation in intact cells IC₅₀ (μg/ml)^a	3-17 fold increase vs control over range 0.10 to 28 μg/ml	minimal complex formation at 9 μg/ml	½ as active vs of (-)-BO	*
P388 cytotoxicity CC₅₀ (μg/ml)^a	0.004	0.50	0.004	*
L1210 cytotoxicity CC₅₀ (μg/ml)^a	0.017	1.7	0.020	*
Antitumor activity i.p.-implanted murine leukaemia P388 0.313mg/kg/day i.p.
Survival days mean:	16.4^b	*	22.2^b	*
T/C%^c	146	*	198	*
Antitumor activity on i.p.-implanted murine leukaemia L1210 0.313mg/kg/day i.p.
Survival days mean:	21.2^d	*	31.4^d	*
T/C%:	155	*	229	*
Antitumor activity on s.c.-implanted colon 26 solid tumor 1.25 mg/kg/day s.c.
Tumor weight mean (g):	0.00^e	*	1.28^e	*
% inhibition	100	*	63	*

^aValues originally reported as μM were converted to μg/ml for this table; ^bcontrol = 11.2 days; ^cRatio (%) of survival time of drug treated animals to control; ^dcontrol = 13.7 days; ^econtrol tumor weight mean = 3.46g.